Arizona State Retirement System boosted its stake in Quanterix Co. (NASDAQ:QTRX) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,392 shares of the company’s stock after purchasing an additional 413 shares during the quarter. Arizona State Retirement System’s holdings in Quanterix were worth $297,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Nisa Investment Advisors LLC acquired a new position in shares of Quanterix during the third quarter valued at about $35,000. HM Payson & Co. acquired a new position in shares of Quanterix during the third quarter valued at about $44,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Quanterix during the third quarter valued at about $90,000. Strs Ohio acquired a new position in shares of Quanterix during the third quarter valued at about $158,000. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Quanterix by 475.3% during the third quarter. BNP Paribas Arbitrage SA now owns 4,971 shares of the company’s stock valued at $168,000 after buying an additional 4,107 shares during the last quarter. Institutional investors and hedge funds own 71.60% of the company’s stock.
In other Quanterix news, SVP David C. Duffy sold 1,667 shares of Quanterix stock in a transaction dated Friday, December 18th. The shares were sold at an average price of $43.82, for a total value of $73,047.94. Following the sale, the senior vice president now owns 42,807 shares of the company’s stock, valued at $1,875,802.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO E Kevin Hrusovsky sold 3,236 shares of Quanterix stock in a transaction dated Tuesday, December 1st. The stock was sold at an average price of $43.75, for a total transaction of $141,575.00. Following the completion of the sale, the chief executive officer now directly owns 1,023,026 shares in the company, valued at approximately $44,757,387.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 76,924 shares of company stock worth $4,181,483. Insiders own 25.40% of the company’s stock.
QTRX has been the subject of a number of analyst reports. SVB Leerink lifted their price objective on shares of Quanterix from $50.00 to $75.00 and gave the company an “outperform” rating in a report on Wednesday, January 27th. Canaccord Genuity raised their price target on shares of Quanterix from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, January 12th. Finally, Zacks Investment Research lowered shares of Quanterix from a “hold” rating to a “sell” rating in a research report on Saturday, January 30th.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Further Reading: LIBOR
Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Co. (NASDAQ:QTRX).
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.